Drug intelligence / Profile preview

XG045

Development stage: Preclinical
Lead developer: Xgene Pharmaceutical Group

Overview

XG045 is an early-stage drug candidate currently in the discovery phase, developed by Xgene Pharmaceutical for the treatment of pain. While Xgene's proprietary technology platform typically focuses on the development of dual-targeting prodrugs—specifically those that chemically combine a cyclooxygenase (COX) inhibitor with a gabapentinoid targeting the α2δ subunit of voltage-gated calcium channels—the specific molecular structure, biological targets, and modality for XG045 have not yet been publicly disclosed. It is part of the company's broader 'Pain Discovery Program' alongside other candidates like XG046.

Beyond the preview

Go deeper on XG045.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XG045.

Explore the full profile